表紙
市場調查報告書
商品編碼
1064773

注意力不足過動障礙的全球市場:2021年∼2027年

Attention Deficit Hyperactivity Disorder Drug Market 2021-2027

出版日期: | 出版商: Orion Market Research Pvt Ltd | 英文 121 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球注意力不足過動障礙的市場規模,在預測期間內預計以大幅度的年複合成長率擴大。新生兒中早產兒數增加,推動該市場的成長。根據馬里蘭大學醫療中心(UMMC),現在有20%的早產兒罹患這個疾病。全球的政府,關注含注意力不足過動症(ADHD)的許多精神障礙罹患的人們增加。政府對該疾病治療的關心,將是更加牽引全球市場。

本報告提供全球注意力不足過動障礙市場相關調查,市場概要,以及各藥物類型,各年齡群,各流通管道,各地區的趨勢,及加入此市場的主要企業簡介等資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

  • 調查範圍
  • 分析師的洞察和目前市場趨勢

第3章 市場決策要素

  • 促進因素
  • 阻礙因素
  • 市場機會

第4章 市場區隔

  • 全球注意力不足過動障礙市場,各藥物類型
    • 刺激劑
    • 非刺激劑
  • 全球注意力不足過動障礙市場,各年齡群
    • 兒童
    • 大人
  • 全球注意力不足過動障礙市場,各流通管道
    • 院內藥局
    • 零售藥局
    • 電子商務

第5章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 其他
  • 其他地區

第6章 企業簡介

  • Eli Lily & Company
  • Johnson & Johnson Services, LLC
  • Lupin Ltd.
  • Mallinckrodt
  • NEOS Therapeutics Inc.
  • Novartis AG
  • Pfizer Inc.
  • Prude Pharma L.P.
  • Shire
目錄
Product Code: OMR2024267

Global Attention deficit hyperactivity disorder drug market Size, Share & Trends Analysis Report By Drug Type (Stimulants, Non-stimulants), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, e-Commerce) by Age Group (Children and Adults), and Forecast (2020-2026)

The global attention deficit hyperactivity disorder drug market is anticipated to grow at a considerable CAGR during the forecast period. The increase in the number of pre-term deliveries of newborns is contributing the growth of the global attention deficit hyperactivity disorder drug market. According to the University of Maryland Medical Center (UMMC), this disease affects 20% of prematurely born babies currently. Governments across the globe are paying attention to the growing number of people suffering from a number of psychological disorders, including attention deficit hyperactivity disorder (ADHD). This focus of government towards treatment of such disease is further likely to drive the global market.

The global attention deficit hyperactivity disorder drug market is segmented based on drug type, distribution channel, and age group. Based on drug type, the attention deficit hyperactivity disorder drug market is segmented into stimulants and non- stimulants. Based on distribution channel, the attention deficit hyperactivity disorder drug market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. Based on age group, the attention deficit hyperactivity disorder drug market is segmented into children and adults.

Geographically, the global attention deficit hyperactivity disorder drug market covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), and the Rest of the World. Some of the companies operating in the global attention deficit hyperactivity disorder drug market include Pfizer Inc., Eli Lilly and Company., Novartis AG., GlaxoSmithKline PLC., Mallinckrodt Pharmaceuticals., Hisamitsu Pharmaceutical Co., Inc., and Johnson & Johnson., among others.

Market Segmentation

1. Global Attention Deficit Hyperactivity Disorder Drug Market Research and Analysis by Drug Type

2. Global Attention Deficit Hyperactivity Disorder Drug Market Research and Analysis by Age Group

3. Global Attention Deficit Hyperactivity Disorder Drug Market Research and Analysis by Distribution Channel

The Report Covers

  • Comprehensive research methodology of the global attention deficit hyperactivity disorder drug market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global attention deficit hyperactivity disorder drug market.
  • Insights about market determinants that are stimulating the global attention deficit hyperactivity disorder drug market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. BY Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Market Determinants

  • 3.1. Motivators
  • 3.2. Restraints
  • 3.3. Opportunities

4. Market Segmentation

  • 4.1. Global Attention Deficit Hyperactivity Disorder Drug Market by Drug Type
    • 4.1.1. Stimulants
    • 4.1.2. Non-Stimulants
  • 4.2. Global Attention Deficit Hyperactivity Disorder Drug Market by Age Group
    • 4.2.1. Children
    • 4.2.2. Adults
  • 4.3. Global Attention Deficit Hyperactivity Disorder Drug Market by Distribution Channel
    • 4.3.1. Hospital Pharmacies
    • 4.3.2. Retail Pharmacies
    • 4.3.3. E-Commerce

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Eli Lily & Company
  • 6.2. Johnson & Johnson Services, LLC
  • 6.3. Lupin Ltd.
  • 6.4. Mallinckrodt
  • 6.5. NEOS Therapeutics Inc.
  • 6.6. Novartis AG
  • 6.7. Pfizer Inc.
  • 6.8. Prude Pharma L.P.
  • 6.9. Shire

LIST OF TABLES

  • 1. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 2. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER STIMULANTS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 3. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER NON-STIMULANTS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY AGE GROUP, 2020-2027 ($ MILLION)
  • 5. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG FOR CHILDREN MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 6. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG FOR ADULTS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 7. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 8. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG FOR HOSPITAL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG FOR RETAIL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 10. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG FOR E-COMMERCE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 11. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 12. NORTH AMERICAN ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 13. NORTH AMERICAN ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 14. NORTH AMERICAN ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY AGE GROUP, 2020-2027 ($ MILLION)
  • 15. NORTH AMERICAN ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 16. EUROPEAN ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 17. EUROPEAN ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 18. EUROPEAN ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY AGE GROUP, 2020-2027 ($ MILLION)
  • 19. EUROPEAN ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 20. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 21. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 22. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY AGE GROUP, 2020-2027 ($ MILLION)
  • 23. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 24. REST OF THE WORLD ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 25. REST OF THE WORLD ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY AGE GROUP, 2020-2027 ($ MILLION)
  • 26. REST OF THE WORLD ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SHARE BY DRUG TYPE, 2020 VS 2027 (%)
  • 2. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SHARE BY AGE GROUP, 2020 VS 2027 (%)
  • 3. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SHARE BY DISTRIBUTION CHANNEL, 2020 VS 2027 (%)
  • 4. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 5. US ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SIZE, 2020-2027 ($ MILLION)
  • 6. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SIZE, 2020-2027 ($ MILLION)
  • 7. UK ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SIZE, 2020-2027 ($ MILLION)
  • 8. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SIZE, 2020-2027 ($ MILLION)
  • 9. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SIZE, 2020-2027 ($ MILLION)
  • 10. ITALY ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SIZE, 2020-2027 ($ MILLION)
  • 11. SPAIN ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SIZE, 2020-2027 ($ MILLION)
  • 12. REST OF EUROPE ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SIZE, 2020-2027 ($ MILLION)
  • 13. INDIA ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SIZE, 2020-2027 ($ MILLION)
  • 14. CHINA ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SIZE, 2020-2027 ($ MILLION)
  • 15. JAPAN ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SIZE, 2020-2027 ($ MILLION)
  • 16. REST OF ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SIZE, 2020-2027 ($ MILLION)
  • 17. REST OF THE WORLD ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SIZE, 2020-2027 ($ MILLION)